Literature DB >> 26571193

Role of pedunculopontine cholinergic neurons in the vulnerability of nigral dopaminergic neurons in Parkinson's disease.

Manale Bensaid1, Patrick P Michel1, Stewart D Clark2, Etienne C Hirsch1, Chantal François3.   

Abstract

Pedunculopontine nucleus (PPN) cholinergic neurons, which exert excitatory nicotinic control over substantia nigra dopaminergic neurons, degenerate in Parkinson's disease (PD). This finding and other studies showing that nicotine, the preferential agonist of nicotinic acetylcholine receptors, is neuroprotective in experimental models of PD suggest that a deficit in PPN excitatory cholinergic inputs might contribute to the death of nigral dopaminergic neurons in PD. To explore this possibility, we used lesion paradigms of dopaminergic and/or cholinergic systems in rats and monkeys. Consistent with our hypothesis, we observed that stereotaxic lesioning of PPN cholinergic neurons with diphtheria toxin coupled to urotensin II resulted in a significant loss of nigral dopaminergic neurons in rats and induced morphological changes in these neurons in macaques. Unexpectedly, a lesion of dopaminergic neurons induced by unilateral striatal injection of 6-hydroxydopamine (6-OHDA) in rats, or by repeated systemic injections of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in macaques, led to a 29% and 7% loss of PPN cholinergic neurons, respectively. Lastly, when the PPN cholinergic lesion was performed in rats in which the dopaminergic lesion induced by 6-OHDA was in progress, loss of cholinergic neurons was more drastic than when each neurotransmitter system was lesioned separately. Thus, our results suggest that strong PPN cholinergic and dopaminergic interactions may be an important mechanism in the pathophysiology of PD.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  6-OHDA; Cholinergic; Diphtheria toxin-urotensin II; Dopamine; MPTP; Parkinson's disease; Pedunculopontine nucleus; Substantia nigra

Mesh:

Substances:

Year:  2015        PMID: 26571193     DOI: 10.1016/j.expneurol.2015.11.004

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  15 in total

1.  Isorhynchophylline Attenuates MPP+-Induced Apoptosis Through Endoplasmic Reticulum Stress- and Mitochondria-Dependent Pathways in PC12 Cells: Involvement of Antioxidant Activity.

Authors:  Xiao-Ming Li; Xiao-Jie Zhang; Miao-Xian Dong
Journal:  Neuromolecular Med       Date:  2017-08-18       Impact factor: 3.843

Review 2.  The pedunclopontine nucleus and Parkinson's disease.

Authors:  Cecilia Tubert; Daniel Galtieri; D James Surmeier
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

3.  Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands.

Authors:  Jian Shen; Xi-Cheng Yang; Ming-Cheng Yu; Li Xiao; Xun-Jie Zhang; Hui-Jiao Sun; Hao Chen; Guan-Xin Pan; Yu-Rong Yan; Si-Chen Wang; Wei Li; Lu Zhou; Qiong Xie; Lin-Qian Yu; Yong-Hui Wang; Li-Ming Shao
Journal:  Acta Pharmacol Sin       Date:  2016-12-05       Impact factor: 6.150

Review 4.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

5.  Targeted activation of midbrain neurons restores locomotor function in mouse models of parkinsonism.

Authors:  Débora Masini; Ole Kiehn
Journal:  Nat Commun       Date:  2022-01-26       Impact factor: 14.919

Review 6.  Dopamine and the Brainstem Locomotor Networks: From Lamprey to Human.

Authors:  Dimitri Ryczko; Réjean Dubuc
Journal:  Front Neurosci       Date:  2017-05-26       Impact factor: 4.677

7.  The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage.

Authors:  Justin Y D Lu; Ping Su; James E M Barber; Joanne E Nash; Anh D Le; Fang Liu; Albert H C Wong
Journal:  PeerJ       Date:  2017-10-19       Impact factor: 2.984

8.  Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson's disease pathogenesis.

Authors:  Iria Carballo-Carbajal; Ariadna Laguna; Jordi Romero-Giménez; Thais Cuadros; Jordi Bové; Marta Martinez-Vicente; Annabelle Parent; Marta Gonzalez-Sepulveda; Núria Peñuelas; Albert Torra; Beatriz Rodríguez-Galván; Andrea Ballabio; Takafumi Hasegawa; Analía Bortolozzi; Ellen Gelpi; Miquel Vila
Journal:  Nat Commun       Date:  2019-03-07       Impact factor: 14.919

9.  Tyrosine Hydroxylase, Vesicular Monoamine Transporter and Dopamine Transporter mRNA Expression in Nigrostriatal Tissue of Rats with Pedunculopontine Neurotoxic Lesion.

Authors:  Lisette Blanco-Lezcano; Esteban Alberti-Amador; Mei-Li Díaz-Hung; María Elena González-Fraguela; Bárbara Estupiñán-Díaz; Teresa Serrano-Sánchez; Liliana Francis-Turner; Javier Jiménez-Martín; Yamilé Vega-Hurtado; Isabel Fernández-Jiménez
Journal:  Behav Sci (Basel)       Date:  2018-02-01

10.  Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.

Authors:  Vincent Perlbarg; Justine Lambert; Benjamin Butler; Mehdi Felfli; Romain Valabrègue; Anne-Laure Privat; Stéphane Lehéricy; Alexandra Petiet
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.